Select Media

Redwood City, Calif. – November 18, 2016 – The Global Initiative for Chronic Obstructive Lung Disease (GOLD) issued a substantial revision to its COPD management recommendations that now includes bronchoscopic lung volume reduction with endobronchial valves as a treatment option for patients with advanced emphysema and absence of collateral ventilation. The updated recommendations are based Read More

Redwood City, Calif. – October 5, 2016 – Pulmonx, a leader in interventional pulmonology, today announced completion of enrollment in its pivotal IDE study – the LIBERATE Trial – a randomized, controlled, multi-center study of the Zephyr® Endobronchial Valve (EBV) in patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). Results from Read More

Cloud-Based Quantitative Computed Tomography (QCT) Analysis Service is Now Commercially AvailableLondon and Redwood City, Calif. – Sept. 1, 2016 – Pulmonx Corporation, today announced the commercial availability of the StratX™ Lung Analysis Platform in countries requiring CE Mark. The StratX Platform is designed to help physicians quickly and reliably identify patients for treatment with Zephyr® Read More

CAUTION: The Zephyr Endobronchial Valve is an investigational device in the US, limited by US law to investigational use.